MYC and lymphoma: In breast cancer, prostate cancer, lung cancer [67], and lymphoma [68], it acts as a definitive oncogene by activating oncogenic transcriptional programs (such as c-Myc) through the methylation of histones (H3R17/R26) and chromatin remodelers (e.g., BAF155).